Endothelin-1 in chronic renal failure and hypertension

Canadian Journal of Physiology and Pharmacology

Volumn 81, Issue 6, 2003, Pages 607-621

  Larivière, Richard ^a,b   Lebel, Marcel ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Angiotensin II; Chronic renal failure; Endothelin 1; Endothelium; Erythropoietin; Hypertension; Nitric oxide

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLSALICYLIC ACID; ATRASENTAN; BOSENTAN; DARUSENTAN; ERYTHROPOIETIN; RIDOGREL;

BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE COURSE; DIURESIS; DRUG POTENCY; EXPERIMENTAL RAT; EXTRACELLULAR SPACE; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SODIUM EXCRETION; UREMIA;

ANIMALS; ENDOTHELIN-1; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RECEPTORS, ENDOTHELIN;

EID: 0037625278     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y03-012     Document Type: Review

References (158)

1. Abassi, Z.A., Tate, J.E., Golomb, E., and Keiser, H.R. 1992. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension, 20: 89-95.
2. Abassi, Z.A., Klein, H., Golomb, E., and Keiser, H.R. 1993a. Urinary endothelin: a possible biological marker of renal damage. Am. J. Hypertens. 6: 1046-1054.
3. Abassi, Z.A., Klein, H., Golomb, E., and Keiser, H.R. 1993b. Regulation of the urinary excretion of endothelin in the rat. Am. J. Hypertens. 6: 453-457.
4. Amann, K., and Ritz, E. 1996. Cardiac structure and function in renal disease. Curr. Opin. Nephrol. Hypertens. 5: 102-106.
5. Amann, K., Neusüb, R., Ritz, E., Irzyniec, T., Wiest, G., and Mall, G. 1995. Changes of vascular architecture independent of blood presure in experimental uremia. Am. J. Hypertens. 8: 409-417.
6. Amann, K., Miltenberger-Miltenyi, G., Simonoviciene, A., Koch, A., Orth, S., and Ritz, E. 2001a. Remodeling of resistance arteries in renal failure: effect of endothelin receptor blockade. J. Am. Soc. Nephrol. 12: 2040-2050.
7. Amann, K., Simonaviciene, A., Medwedewa, T., Koch, A., Orth, S., Gross, M.L., Haas, C., Kuhlmann, A., Linz, W., Scholkens, B., and Ritz, E. 2001b. Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J. Am. Soc. Nephrol. 12: 2572-2584.
8. Anagnostou, A., Liu, Z., Steiner, M., Chin, K., Lee, E.S., Kessimian, N., and Noguchi, C.T. 1994. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 91: 3974-3978.
9. Barton, M., Vos, I., Shaw, S., Boer, P., d'Uscio, L.V., Grone, H.J., Rabelink, T.J., Lattmann, T., Moreau, P., and Lüscher, T.F. 2000. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J. Am. Soc. Nephrol. 11: 835-846.
10. Baylis, C., Mitruka, B., and Deng, A. 1992. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90: 278-281.
11. Benigni, A. 2000. Endothelin antagonists in renal disease. Kidney Int. 57: 1778-1794.
12. Benigni, A., Perico, N., Gaspari, F., Zoja, C., Bellizzi, L., Gabanelli, M., and Remuzzi, G. 1991. Increased renal endothelin production in rats with reduced renal mass. Am. J. Physiol. 260: F331-F339.
13. Benigni, A., Zoja, C., Corna, D., Orisio, S., Longaretti, L., Bertani, T., and Remuzzi, G. 1993. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 44: 440-444.
14. Benigni, A., Zola, C., Corna, D., Orisio, S., Facchinetti, D., Benati, L., and Remuzzi, G. 1996. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am. J. Kidney Dis. 27: 416-423.
15. Benigni, A., Corna, D., Maffi, R., Benedetti, G., Zoja, C., and Remuzzi, G. 1998. Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy. Kidney Int. 54: 353-359.
16. Berglund, B., and Ekblom, B. 1991. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J. Intern. Med. 229: 125-130.
17. B receptors induces BQ-123-sensitive hypertension in the mouse. Hypertension 36: 1002-1007.
18. Blum, M., Yachnin, T., Wollman, Y., Chernihovsky, T., Peer, G., Grosskopf, I., Kaplan, E., Silverberg, D., Cabili, S., and Iaina, A. 1998. Low nitric oxide production in patients with chronic renal failure. Nephron, 79: 265-268.
19. Bode-Boger, S.M., Boger, R.H., Kuhn, M., Radermacher, J., and Frolich, J.C. 1996. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 50: 1255-1261.
20. Border, W.A., Noble, N.A., and Ketteler, M. 1995. TGF-b: A cytokine mediator of glomerulosclerosis and a target for therapeutic intervention. Kidney Int. 47(Suppl. 49): S-59-S-61.
21. Boulanger, C., and Lüscher, T.F. 1990. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85: 587-590.
22. Bremnes, T., Paasche, J.D., Mehlum, A., Sandberg, C., Bremnes, B., and Attramadal, H. 2000. Regulation and intracellular trafticking pathways of the endothelin receptors. J. Biol. Chem. 275: 17 596-17 604.
23. Brochu, E., Lacasse-M., S., Larivière, R., Kingma, I., Grose, J.H., and Lebel, M. 1999a. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J. Am. Soc. Nephrol. 10: 1440-1446.
24. A receptor blockade prevents the progression of renal failure and hypertension in uremic rats. Nephrol. Dial. Transplant. 14: 1881-1888.
25. Brooks, D.P., Contino, L.C., Storer, B., and Ohlstein, E.H. 1991. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br. J. Pharmacol. 104: 987-989.
26. B receptor in local clearance of endothelin-1 in rat heart: studies with the antagonists PD 155080 and BQ-123. FEBS Lett. 396: 238-242.
27. Bruzzi, I., Benigni, A., and Remuzzi, G. 1997a. Role of increased glomerular protein traffic in the progression of renal failure. Kidney Int. Suppl 62: S29-31.
28. Bruzzi, I., Corna, D., Zoja, C., Orisio, S., Schiffrin, E.L., Cavallotti, D., Remuzzi, G., and Benigni, A. 1997b. Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am. J. Pathol. 151: 1241-1247.
29. Campese, V.M. 1986. Management of hypertension in chronic dialysis patients. In Dialysis therapy. Edited by A.R. Nissenson and R.N. Fine. Handley and Belfus Inc., Philadelphia. pp. 132-166.
30. Caravaca, F., Pizarro, J.L., Arrobas, M., Cubero, J.J., Garcia, M.C., and Perez-Miranda, M. 1994. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int. 45: 845-851.
31. Caravaca, F., Lopez-Minguez, J.R., Arrobas, M., Cubero, J., Pizarro, J.L., Cid, M.C., Sanchez-Casado, E., and Miranda, M.P. 1995. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrol. Dial. Transplant. 10: 1720-1724.
32. Carlini, R., Obialo, C.I., and Rothstein, M. 1993a. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am. J. Hypertens. 6: 103-107.
33. Carlini, R.G., Dusso, A.S., Obialo, C.I., Alvarez, U.M., and Rothstein, M. 1993b. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 43: 1010-1014.
34. Chen, L., McNeill, J.R., Wilson, T.W., and Gopalakrishnan, V. 1995. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin. Hypertension, 26: 83-88.
35. Clavell, A.L., Stingo, A.J., Margulies, K.B., Brandt, R.R., and Burnett, J.C.J. 1995. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am. J. Physiol. 268: F455-F460.
36. B receptor antagonist Ro 46- 8443. FEBS Lett. 383: 42-45.
37. Cybulsky, A.V., Stewart, D.J., and Cybulsky, M.I. 1993. Glomerular epithelial cells produce endothelin-1. J. Am. Soc. Nephrol. 3: 1398-1404.
38. D'Amours, M., Lebel, M., Grose, J.H., and Larivière, R. 1999. Renal and vascular effects of chronic nitric oxide synthase inhibition: involvement of endothelin-1 and angiotensin II. Can. J. Physiol. Pharmacol. 77: 8-16.
39. D'Amours, M., Lacasse-M., S., Lebel, M, René de Cotret, P., and Larivière, R. 2000. Involvement of transforming growth factor-betal and endothelin-1 in uremic hypertensive rats. J. Hypertens. 18(Suppl. 4): S217.
40. Davenport, A.P., Ashby, M.J., Easton, P., Ella, S., Bedford, J., Dickerson, C., Nunez, D.J., Capper, S.J., and Brown, M.J. 1990. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin. Sci. 78: 261-264.
41. A receptors predominate in the human vasculature and mediate constriction. J. Cardiovasc. Pharmacol. 26: S265-267.
42. 2/prostaglandin endoperoxide receptor blockade combined in one molecule-I. Biochemical profile in vitro. Thromb. Haemost. 61: 35-42.
43. De Nucci, G., Thomas, R., D'Orléans-Juste, P., Antunes, E., Walder, C., and Vane, J.R. 1988. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U.S.A. 85: 9797-9800.
44. Deng, A., and Baylis, C. 1993. Locally produced EDRF control preglomerular resistance and ultrafiltration coefficient. Am. J. Physiol. 264: F212-F215.
45. Dumont, Y., D'Amours, M., Lebel, M., and Ladvière, R. 2001a. Supplementation with a low dose of L-arginine reduces blood pressure and endothelin-1 production in hypertensive uraemic rats. Nephrol. Dial. Transplant. 16: 746-754.
46. Dumont, Y., D'Amours, M., Lebel, M., and Larivière, R. 2001b. Blood pressure-independent effects of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J. Hypertens. 19: 1479-1487.
47. Eddy, A.A. 2000. Molecular basis of renal fibrosis. Pediatr Nephrol. 15: 290-301.
48. Edwards, R.M., and Trizna, W. 1993. Modulation of glomerular arteriolar tone by nitric oxide synthase inhibitors. J. Am. Soc. Nephrol. 4: 1127-1132.
49. B receptors increases glomerular cGMP via an L-arginine-dependent pathway. Am. J. Physiol. 263: F1020-F1025.
50. Eggena, P., Willsey, P., Jamgotchian, N., Truckenbrod, L., Hu, M.S., Barrett, J.D., Eggena, M.P., Clegg, K., Nakhoul, F., and Lee, D.B. 1991. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am. J. Physiol. 261: E642-E646.
51. Emori, T., Hirata, Y., Ohta, K., Shichiri, M., and Marumo, F. 1989. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem. Biophys. Res. Commun. 160: 93-100.
52. Firth, J.D., and Ratcliffe, P.J. 1992. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J. Clin. Invest. 90: 1023-1031.
53. Fischl, M., Galpin, J.E., Levine, J.D.; Groopman, J.E., Henry, D.H., Kennedy, P., et al. 1990. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N. Engl. J. Med. 322: 1488-1493.
54. Forbes, J.M., Hewitson, T.D., Becker, G.J., and Jones, C.L. 2001. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int. 59: 1333-1341.
55. Fukuda, K., Yanagida, T., Okuda, S., Tamaki, K., Ando, T., and Fusjishima, M. 1996. Role of endothelin as a mitogen in experimental glomerulonephritis in rats. Kidney Int. 49: 1320-1329.
56. B receptors in rats. Biochem. Biophys. Res. Commun. 199: 1461-1465.
57. B receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. 50: 962-972.
58. Gomez-Garre, D., Ruiz Ortega, M., Ortego, M., Largo, R., Lopez Armada, M.J., Plaza, J.J., Gonzalez, E., and Egido, J. 1996b. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension, 27: 885-892.
59. Gonzalez, E., Jawerbaum, A., Sinner, D., Pustovrh, C., Xaus, C., Peralta, C., Gomez, G., Rosello-Catafau, J., Gelpi, E., and Gimeno, M. 1999. Evolution of streptozotocin-pancreatic damage in the rat: modulatory effect of endothelins on the nitridergic and prostanoid pathway. Nitric Oxide, 3: 459-466.
60. Gonzalez, W., Chen, Z., and Damon, D.H. 2001. Transforming growth factor-beta regulation of endothelin expression in rat vascular cell and organ cultures. J. Cardiovasc. Pharmacol. 37: 219-226.
61. B receptor and nitric oxide synthase blockade induce BQ-123-sensitive pressor effects in the rabbit. Hypertension, 30: 1204-1209.
62. Canadian Erythropoietin Study Group. 1991. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group. Am. J. Nephrol. 11: 23-26.
63. Hahn, A.W.A., Regenass, S., Kern, F., Buhler, F.R., and Resink, T.J. 1993. Expression of soluble and insoluble fibronectin in rat aorta: effects of angiotensin II and endothelin-1. Biochem. Biophys. Res. Commun. 192: 189-197.
64. Hand, M.F., Haynes, W.G., and Webb, D.J. 1998. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int. 53: 1068-1077.
65. Harris, P.J., Zhuo, J., Mendelsohn, F.A., and Skinner, S.L. 1991. Haemodynamic and renal tubular effects of low doses of endothelin in anaesthetized rats. J. Physiol. 433: 25-39.
66. Herman, W.H., Emancipator, S.N., Rhoten, R.L., and Simonson, M.S. 1998. Vascular and glomerular expression of endothelin-1 in normal human kidney. Am. J. Physiol. 275: F8-F17.
67. Hirata, Y., Takagi, Y., Fukuda, Y., and Marumo, E 1989. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis, 78: 225-228.
68. Hirata, Y., Emori, T., Eguchi, S., Kanno, K., Imai, T., Ohta, K., and Marumo, F. 1993. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest. 91: 1367-1373.
69. Hocher, B., Thone-Reineke, C., Rohmeiss, P., Schmager, F., Slowinski, T., Burst, V., Siegmund, F., Quertermous, T., Bauer, C., Neumayer, H.H., Schleuning, W.D., and Theuring, F. 1997. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J. Clin. Invest. 99: 1380-1389.
70. B receptors. Hypertension, 35: 732-739.
71. Hori, K., Onoyama, K., Iseki, K., Fujimi, S., and Fujishima, M. 1990. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients. Clin. Nephrol. 33: 293-298.
72. Huang, P.L., Huang, Z., Mashimo, H., Bloch, K.D., Moskowitz, M.A., Bevan, J.A., and Fishman, M.C. 1995. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature (London), 377: 239-242.
73. Hughes, A.K., Cline, R.C., and Kohan, D.E. 1992. Alterations in renal endothelin-1 production in the spontaneously hypertensive rat. Hypertension, 20: 666-673.
74. Ihling, C., Szombathy, T., Bohrmann, B., Brockhaus, M., Schaefer, H.E., and Loeffler, B.M. 2001. Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis. Circulation, 104: 864-869.
75. Ikeda, T., Yuhara, M., Gomi, T., Ishimitsu, T., and Uehara, Y. 1989. Alteration of vascular thromboxane in rats with subtotal renal ablation. Prostaglandins Leukot. Essent. Fatty Acids, 37: 157-161.
76. Ito, S., Juncos, L.A., Nushiro, N., Johnson, C.S., and Carretero, O.A. 1991. Endothelium-derived relaxing factor modulates endothelin action in afferent arterioles. Hypertension, 17: 1052-1056.
77. Joannides, R., Bakkali, E.H., Le Roy, F., Rivault, O., Godin, M., Moore, N., Fillastre, J.P., and Thuillez, C. 1997. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol. Dial. Transplant. 12: 2623-2628.
78. Jougasaki, M., Schirger, J.A., Simari, R.D., and Burnett, J.C., Jr. 1998. Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. Hypertension, 32: 917-922.
79. Junaid, A., Hostetter, TH., and Rosenberg, M.E. 1997. Interaction of angiotensin II and TGF-b1 in the rat remnant kidney. J. Am. Soc. Nephrol. 8: 1732-1738.
80. Kakinuma, Y., Kawamura, T., Bills, T., Yoshioka, T., Ichikawa, I., and Fogo, A. 1992. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int. 42: 46-55.
81. Karet, F.E., and Davenport, A.P. 1996. Localization of endothelin peptides in human kidney. Kidney Int. 49: 382-387.
82. Katoh, T., Chang, H., Uchida, S., Okuda, T., and Kurokawa, K. 1990. Direct effects of endothelin in the rat kidney. Am. J. Physiol. 258: 397-403.
83. Kaupke, C.J., Kim, S., and Vaziri, N.D. 1994. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J. Am. Soc. Nephrol. 4: 1874-1878.
84. Kitamura, K., Tanaka, T., Kato, J., Ogawa, T., Eto, T., and Tanaka, K. 1989. Immunoreactive endothelin in rat kidney inner medulla: marked decrease in spontaneously hypertensive rats. Biochem. Biophys. Res. Commun. 162: 38-44.
85. Klag, M.J., Whelton, P.K., Randall, B.L., Neaton, J.D., Brancati, F.L., Ford, C.E., Shulman, N.B., and Stamler, J. 1996. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 334: 13-18.
86. Kohan, D.E., and Padilla, E. 1993. Osmolar regulation of endothelin-1 production by rat inner medullary collecting duct. J. Clin. Invest. 91: 1235-1240.
87. Kohan, D.E., Padilla, E., and Hughes, A.K. 1993. Endothelin B receptor mediates ET-1 effects on cAMP and PGE2 accumulation in rat IMCD. Am. J. Physiol. 265: F670-676.
88. Koyama, H., Nishzawa, Y., Morii, H., Tabata, T., Inoue, T., and Yamaji, T. 1989. Plasma endothelin levels in patients with uremia. Lancet, 1: 991-992.
89. Kuriyama, S., Tomonari, H., and Hosoya, T. 1999. Antiplatelet therapy decreases the incidence of erythropoietin-induced hypertension in predialysis patients. Clin. Exp. Hypertens. 21: 213-222.
90. Lacasse, M.S., Kingma, I., Lariviere, R., Grose, J.H., and Lebel, M. 1997. Uremia enhances the blood pressure response to erythropoietin. Clin. Exp. Hypertens. 19: 389-401.
91. Lafayette, R.A., Mayer, G., Park, S.K., and Meyer, T.W. 1992. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 90: 766-771.
92. Larivière, R., D'Amours, M., Lebel, M., Kingma, I., Grose, J.H., and Caron, L. 1997. Increased immunoreactive endothelin-1 levels in blood vessels and glomeruli of rats with reduced renal mass. Kidney Blood Press. Res. 20: 372-380.
93. Larivière, R., Lebel, M., Kingma, I., and Grose, J.H. 1998a. Increased tissue angiotensin II induces endothelin-1 production in blood vessels and glomeruli of hypertensive uremic rats. J. Hypertens. 16: S96.
94. Larivière, R., Lebel, M., Kingma, I., Grose, J.H., and Boucher, D. 1998b. Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am. J. Hypertens. 11: 989-997.
95. Larivière, R., Robitaille, G., D'Amours, M., Lacasse-M., S., Boucher, D., Dumont, Y., and Lebel, M. 2000. Mechanisms of renal damage in rats with chronic nitric oxide synthase inhibition: role of endothelin-1 and angiotensin II. J. Am. Soc. Nephrol. 11: 336A.
96. Lebel, M., Grose, J.H., Kingma, I., and Langlois, S. 1994. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients: effect of subcutaneous erythropoietin replacement therapy. Clin. Exper. Hypertens. 16: 565-575.
97. Lebel, M., Kingma, I., Grose, J.H., and Langlois, S. 1995. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients. Am. J. Hypertens. 8: 545-551.
98. Lebel, M., Kingma, I., Grose, J.H., and Langlois, S. 1998a. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J. Am. Soc. Nephrol. 9: 97-104.
99. Lebel, M., Lacasse-M., S., Larivière, R., Kingma, I., and Grose, J.H. 1998b. Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin. Exper. Hypertens. 20: 939-951.
100. Lebel, M., Moreau, V., Grose, J.H., Kingma, I., and Langlois, S. 1998c. Plasma and peritoneal endothelin levels and blood pressure in CAPD patients with or without erythropoietin replacement therapy. Clin. Nephrol. 49: 313-318.
101. Lehrke, I., Waldherr, R., Ritz, E., and Wagner, J. 2001. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J. Am. Soc. Nephrol. 12: 2321-2329.
102. Lerman, A., Sandok, E.K., Hilderbrand, F.L., and Burnett, J.C.J. 1992. Inhibition of endothelium-derived relaxing factor enhances endothelin-mediated vasoconstriction. Circulation, 85: 1894-1898.
103. Lin, H., Sangmal, M., Smith, M.J., Jr., and Young, D.B. 1993. Effect of endothelin-1 on glomerular hydraulic pressure and renin release in dogs. Hypertension, 21: 845-851.
104. Lindner, A., Charra, B., Sherrard, D.J., and Scribner, B.H. 1974. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 290: 697-701.
105. Ludwig, H., Fritz, E., Kotzmann, H., Hocker, P., Gisslinger, H., and Barnas, U. 1990. Erythropoietin treatment of anemia associated with multiple myeloma. N. Engl. J. Med. 322: 1693-1699.
106. Marsden, P.A., Dorfman, D.M., Collins, T., Brenner, B.M., Orkin, S.H., and Ballerman, B.J. 1991. Regulated expression of endothelin-1 in glomerular capillary endothelial cells. Am. J. Physiol. 261: F117-F125.
107. Marsen, T.A., Schramek, H., and Dunn, M.J. 1994. Renal actions of endothelin: linking cellular signaling pathways to kidney disease. Kidney Int. 45: 336-344.
108. Mathana, J., and Singhal, P.C. 1995. L-arginine supplementation antagonizes the effects of angiotensin II and endothelin I on mesangial cell proliferation. Cell Physiol. Biochem. 5: 176-192.
109. Matsuura, T., Miura, K., Ebara, T., Yukimura, T., Yamanaka, S., Kim, S., and Iwao, H. 1997. Renal vascular effects of the selective endothelin receptor antagonists in anaesthetized rats. Br. J. Pharmacol. 122: 81-86.
110. Mazhar, A.R., Johnson, R.J., Gillen, D., Stivelman, J.C., Ryan, M.J., Davis, C.L., and Stehman-Breen, C.O. 2001. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 60: 324-332.
111. McIntyre, M., Bohr, D., and Dominiczak, A. 1999. Endothelial function in hypertension: the role of superoxide anion. Hypertension, 34: 539-545.
112. Moreau, P., Takase, H., and Luscher, T.F. 1996. Effect of endothelin antagonists on the responses to prostanoid endothelium-derived contracting factor. Br. J. Pharmacol. 118: 1429-1432.
113. A-receptor antagonist. Circulation, 96: 1593-1597.
114. Moreau, C., Lariviere, R., Kingma, I., Grose, J.H., and Lebel, M. 1999. Eicosanoid imbalance in erythropoïetin-induced hypertension. Can. J. Cardiol. 15: 237D.
115. Moreau, C., Lariviere, R., Kingma, I., Grose, J.H., and Lebel, M. 2000. Chronic nitric oxide inhibition aggravates hypertension in erythropoietin-treated renal failure rats. Clin. Exp. Hypertens. 22: 663-674.
116. Morris, S.T., and Jardine, A.G. 2000. The vascular endothelium in chronic renal failure. J. Nephrol. 13: 96-105.
117. Morris, S.T., McMurray, J.J., Spiers, A., and Jardine, A.G. 2001. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 60: 1077-1082.
118. Nabokov, A., Amann, K., Wagner, J., Gehlen, F., Münter, K., and Ritz, E. 1996. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol. Dial. Transplant. 11: 514-520.
119. Nabokov, A., Amann, K., Wessels, S., Münter, K., Wagner, J., and Ritz, E. 1999. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. 55: 512-519.
120. Nadler, S.P., Zimpelmann, J.A., and Hébert, R.L. 1992. Endothelin inhibits vasopressin-stimulated water permeability in rat terminal inner medullary collecting duct. J. Clin. Invest. 90: 1458-1466.
121. Ni, Z., Wang, X.Q., and Vaziri, N.D. 1998. Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade. Hypertension, 32: 724-729.
122. Nord, E.P. 1993. Renal actions of endothelin. Kidney Int. 44: 451-463.
123. Ohuchi, T., Yanagisawa, M., and Gariepy, C.E. 2000. Renal tubular effects of endothelin-B receptor signaling: its role in cardiovascular homeostasis and extracellular volume regulation. Curr. Opin. Nephrol. Hypertens. 9: 435-439.
124. A-selective receptor antagonist. J. Pharmacol. Exp. Ther. 276: 473-481.
125. Orisio, S., Benigni, A., Bruzzi, I., Corna, D., Perico, N., Zoja, C., Benatti, L., and Remuzzi, G. 1993. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 43: 354-358.
126. A-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension, 31: 995-1001.
127. A receptor blocker LU 135252 prevents chronic transplant nephropathy in the "Fisher to Lewis" model. J. Am. Soc. Nephrol. 10: 387-391.
128. Orth, S.R., Amann, K., Gehlen, F., Unger, L., Wagner, J., Raschack, M., and Ritz, E. 2000. Adult human mesangial cells (HMCs) express endothelin-B-receptors which mediate endothelin-1-induced cell growth. J. Cardiovasc. Pharmacol. 36: S232-237.
129. Pincus, T., Olsen, N.J., Russell, I.J., Wolfe, F., Harris, E.R., Schnitzer, T.J., Boccagno, J.A., and Krantz, S.B. 1990. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am. J. Med. 89: 161-168.
130. B receptor-mediated NO release. Am. J. Physiol. 279: F326-F333.
131. Pollock, D.M. 2000. Renal endothelin in hypertension. Cur. Opin. Nephrol. Hypertens. 9: 157-164.
132. Pollock, D.M., and Pollock, J.S. 2001. Evidence for endothelin involvement in the response to high salt. Am. J. Physiol. Renal Physiol. 281: F144-F150.
133. Ribeiro, M.O., Antunes, E., De Nucci, G., Lovisolo, S.M., and Zatz, R. 1992. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension, 20: 298-303.
134. Riggleman, A., Harvey, J., and Baylis, C. 2001. Endothelin mediates some of the renal actions of acutely administered angiotensin II. Hypertension, 38: 105-109.
135. Roczniak, A., Frayer, J., Levine, D., and Burns, K. 1999. Down-regulation of neuronal nitric oxide in the rat remnant kidney. J. Am. Soc. Nephrol. 10: 704-713.
136. Rodrigue, M.E., Lariviere, R., and Lebel, M. 2001. Induction of the prepro-endothelin-1 gene expression by erythropoietin in vitro and in vivo. J. Am. Soc. Nephrol. 12: 576A.
137. Rodrigue, M.E., Moreau, C., Larivièe, R., and Lebel, M. 2003. Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J. Cardiovasc. Pharmacol. 41: 388-395.
138. Rudic, R., Shesely, E., Maeda, N., Smithies, O., Segal, S., and Sessa, W. 1998. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Invest. 101: 731-736.
139. Ruiz-Ortega, M., Gomez Garre, D., Alcazar, R., Palacios, I., Bustos, C., Gonzalez, S., Plaza, J.J., Gonzalez, E., and Egido, J. 1994. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J. Hypertens. 12 (Suppl. 4): S51-S58.
140. B receptors mediate contraction to endothelin-1 in human blood vessels. Circulation, 89: 1203-1208.
141. Simonson, M.S., and Dunn, M.J. 1993. Endothelin peptides and the kidney. Annu. Rev. Physiol. 55: 249-265.
142. + exchange, c-fos expression, and mitogenesis in rat mesangial cells. J. Clin. Invest. 83: 708-712.
143. Telemaque, S., Lemaire, D., Claing, A., and D'Orleans-Juste, P. 1992. Phosphoramidon-sensitive effects of big endothelins in the perfused rabbit kidney. Hypertension, 20: 518-523.
144. A receptors in the perfused rabbit kidney. Eur. J. Pharmacol. 237: 275-281.
145. Terada, Y., Tomita, K., Nonoguchi, H., and Marumo, F. 1992. Different localization of two types of endothelin receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J. Clin. Invest. 90: 107-112.
146. Tornig, J., Gross, M.L., Simonaviciene, A., Mall, G., Ritz, E., and Amann, K. 1999. Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure. J. Am. Soc. Nephrol. 10: 77-83.
147. Ujiie, K., Terada, Y., Nonoguchi, H., Shinohara, M., Tomita, K., and Marumo, F. 1992. Messenger RNA expression and synthesis of endothelin-1 along rat nephron segments. J. Clin. Invest. 90: 1043-1048.
148. Vallance, P., Leone, A., Calver, A., Collier, J., and Moncada, S. 1992. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 339: 572-575.
149. Vaziri, N.D., Zhou, X.J., Naqvi, F., Smith, J., Oveisi, F., Wang, Z.Q., and Purdy, R.E. 1996. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am. J. Physiol. 271: E113-E122.
150. Vaziri, N.D., Oveisi, F., and Ding, Y. 1998. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int. 53: 1748-1754.
151. Wada, Y., Matsuoka, H., Tamai, O., Kohno, K., Okuda, S., and Imaizumi, T. 1999. Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am. J. Hypertens. 12: 980-987.
152. Wagner, O.F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P.J., Schneider, B., Waldhausl, W., and Binder, B.R. 1992. Polar secretion of endothelin-1 by cultured endothelial cells. J. Biol. Chem. 267: 16066-16068.
153. Wang, A., Holcslaw, T., Bashore, T.M., Freed, M.I., Miller, D., Rudnick, M.R., Szerlip, H., Thames, M.D., Davidson, C.J., Shusterman, N., and Schwab, S.J. 2000. Exacerbation of radio-contrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 57: 1675-1680.
154. Wilkes, B., Susin, M., Mento, P.F., Macica, C.M., Girardi, E.P., Boss, E., and Nord, E.P. 1991. Localization of endothelin-like immunoreactivity in rat kidneys. Am. J. Physiol. 260: F913-F920.
155. Wong, N.L., Wong, B.P., and Tsui, J.K. 2000. Vasopressin regulates endothelin-B receptor in rat inner medullary collecting duct. Am. J. Physiol. Renal Physiol. 278: F369-F374.
156. +-ATPase in intact renal tubular epithelial cells. Am. J. Physiol. 257: C1101-C1107.
157. 2 analogue. Lab. Invest. 64: 16-20.
158. Zoja, C., Liu, X.H., Abbate, M., Corna, D., Schiffrin, E.L., Remuzzi, G., and Benigni, A. 1998. Angiotensin II blockade limits tubular protein overreabsorption and the consequent upregulation of endothelin-1 gene in experimental membranous nephropathy. Exp. Nephrol. 6: 121-131.